Literature DB >> 21109321

T1-2 anal carcinoma requires elective inguinal radiation treatment--the results of Trans Tasman Radiation Oncology Group study TROG 99.02.

John H L Matthews1, Bryan H Burmeister, Martin Borg, Anne L Capp, David Joseph, Kerin M Thompson, Paul I Thompson, Jennifer A Harvey, Nigel A Spry.   

Abstract

BACKGROUND AND
PURPOSE: Elective inguinal irradiation increases morbidity. We describe outcomes of moderate intensity chemoradiation treating anal canal and adjacent pelvic nodes only.
MATERIAL AND METHODS: Forty patients with T1-2, N0 anal carcinoma were enrolled between March 1999 and March 2003. Inguinal nodes were NOT electively irradiated. The anal canal and regional pelvic nodes received 36 Gy/20# over 4 weeks, and 2 weeks later the anal canal was boosted with 14.4 Gy/8#. Chemotherapy was 5 fluorouracil 800 mg/m(2)/day on days 1-4 and 36-39, and Mitomycin C 10mg/m(2) on day 1.
RESULTS: Median follow-up was 44 months. Complete response was 95%. Four year results were; overall survival 71%, local control 82%, and colostomy-free survival (including salvage) 85%. Inguinal failure occurred in 22.5% but was isolated in only 12.5%. Treatment was well tolerated acutely with no toxic deaths. Severe late toxicity occurred in 7.5%.
CONCLUSIONS: This moderate dose 'non inguinal' chemoradiation regimen resulted in modest acute toxicity, minimal long term morbidity and local control in line with other series. However staging failed to identify 12.5% of patients whose isolated inguinal failure might have been prevented by elective irradiation. Without more effective staging, all patients should receive elective inguinal irradiation. Copyright Â
© 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21109321     DOI: 10.1016/j.radonc.2010.10.005

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  11 in total

Review 1.  New approach to anal cancer: individualized therapy based on sentinel lymph node biopsy.

Authors:  Paola De Nardi; Michele Carvello; Carlo Staudacher
Journal:  World J Gastroenterol       Date:  2012-11-28       Impact factor: 5.742

2.  Radio-chemotherapy in anal cancer: Institutional experience at a large radiation oncology center in Chile.

Authors:  Moisés Russo; Valentina Ovalle
Journal:  Rep Pract Oncol Radiother       Date:  2014-06-30

Review 3.  Shifting paradigm in the management of anal canal carcinoma.

Authors:  Supriya Mallick; Rony Benson; P K Julka; G K Rath
Journal:  J Gastrointest Cancer       Date:  2015-03

4.  Reduced radiation dose for elective nodal irradiation in node-negative anal cancer: back to the roots?

Authors:  Christoph Henkenberens; Daniela Meinecke; Stoll Michael; Michael Bremer; Hans Christiansen
Journal:  Strahlenther Onkol       Date:  2015-08-26       Impact factor: 3.621

Review 5.  Squamous-cell carcinoma of the anus: progress in radiotherapy treatment.

Authors:  Rob Glynne-Jones; David Tan; Robert Hughes; Peter Hoskin
Journal:  Nat Rev Clin Oncol       Date:  2016-01-27       Impact factor: 66.675

6.  Comparison of four 3D conformal treatment techniques to optimise radiotherapy treatment for anal cancer.

Authors:  Alison Cray; Cathy Markham; Michelle Ryan; Alan Herschtal; Samuel Y Ngan; Sarat Chander
Journal:  J Med Radiat Sci       Date:  2014-11-17

7.  Anal adenocarcinoma requires prophylactic inguinal nodal treatment: Results from a single Chinese institution.

Authors:  Zhen Su; Zhan-Wen Guo; Yan-Ping Mao; Jie Tang; Xiao-Wen Lan; Fang-Yun Xie; Qun Li
Journal:  J Cancer       Date:  2017-04-09       Impact factor: 4.207

8.  Initial Results from the Royal College of Radiologists' UK National Audit of Anal Cancer Radiotherapy 2015.

Authors:  R Muirhead; K Drinkwater; S M O'Cathail; R Adams; R Glynne-Jones; M Harrison; M A Hawkins; D Sebag-Montefiore; D C Gilbert
Journal:  Clin Oncol (R Coll Radiol)       Date:  2016-10-31       Impact factor: 4.126

9.  Post-operative radiation therapy with or without chemotherapy for anal squamous cell carcinoma incidentally discovered after local excision: a propensity score matched analysis of retrospective multicenter study.

Authors:  Kyung Su Kim; Ah Ram Chang; Kyubo Kim; Hyeon Kang Koh; Won Il Jang; Hae Jin Park; Ji Hyun Chang; Mi-Sook Kim
Journal:  Br J Radiol       Date:  2019-12-17       Impact factor: 3.039

10.  Pulse-dose-rate interstitial brachytherapy in anal squamous cell carcinoma: clinical outcomes and patients' health quality perception.

Authors:  Rémi Bourdais; Samir Achkar; Sophie Espenel; Sophie Bockel; Laetitia Chauffert-Yvart; Florence Ravet de Mellis; Minh-Hanh Ta; Wassila Boukhelif; Jérôme Durand-Labrunie; Pascal Burtin; Christine Haie-Meder; Eric Deutsch; Cyrus Chargari
Journal:  J Contemp Brachytherapy       Date:  2021-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.